In fact, most of the drugs currently used to treat RA are anti-inflammatory immune modulators, like Infliximab (anti-TNFα), Abatacept (CTLA-4Ig), Tocilizumab (anti-IL6R), Rituximab (anti-CD20), Anakinra (IL1-R antagonist), Canakinumab (anti-IL1), and Tofacitinib (JAK inhibitor). This evidence concerns the gene IL1R1 and rheumatoid arthritis.